Join Dr Richard Knight at the Digital AMR Conference

Dr Richard Knight | Anti Microbial Resistance | ApconiX

Join Dr Richard Knight, Co-founder and Director of ApconiX, Dr Peter Warn consultant at Magic Bullet Consulting, and Aleksander Danilovski, Chief Scientific Officer & Senior Vice President, Global R&D and Regulatory Affairs at Xelia at the 4th AMR Conference as they discuss the Top 10 Mistakes in Antibacterial Development”.

In view of the continuing uncertain situation and travel restrictions due to the COVID-19 pandemic the 4th AMR Conference is a digital format in the week of 24–28 August 2020.

“Top 10 Mistakes in Antibacterial Development” is on the first day of the conference at 11:00 to 12:30 Central European Summer Time.  The theme of the day is “Lessons Learned from COVID-19”.  Jointly organised by Novo REPAIR Impact Fund, CARB-X, GARDP and Wellcome Trust, the session will be moderated by Dr Ursula Theuretzbacher, Founder of the Center for Anti-Infective Agents (CEFAIA).

Richard will be discussing 3 safety considerations centred around earlier engagement of safety in the selection of clinical candidates.

The AMR Conference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to the market.

The current global health crisis caused by COVID-19 shows more than ever the importance of infectious diseases expertise and the high need for further fighting against antimicrobial resistance (AMR). A cross-sectoral international dialogue with all stakeholders involved will be crucial to help implement innovative therapies and diagnostics in the clinical practice globally.

Dr Richard Knight is a co-founder of ApconiX, an expert toxicologist with more than 20 years of drug development experience gained in AstraZeneca, where he was part of the Drug Safety and Oncology Leadership Teams.  Richard has worked on projects in multiple therapy areas involving small molecules, biologics, proteins and oligonucleotides.   He has an in-depth understanding of drug discovery and drug development and has been directly involved in bringing over 35 new candidate drugs to clinical trials and 6 to marketing approval.  He uses his extensive experience to bring an innovative, science-led and pragmatic approach to the design and delivery of nonclinical safety programmes.

Dr Peter Warn is a consultant at Magic Bullet Consulting with expertise in the development of antimicrobial agents. Prior to this, he was Senior Vice President of Anti-infective Discovery at Evotec, where he led antimicrobial discovery programmes and had scientific oversight of external client contracts. Peter was a founder and Chief Scientific Officer of Euprotec before the company was acquired by Evotec. Previously he was a senior lecturer at the University of Manchester, running a research group investigating the pathogenesis and treatment of severe infections. He has also lectured within Molecular Parasitology at the University of Oxford and, was a clinical scientist in Public Health England.

Dr Aleksander Danilovski is Chief Scientific Officer (CSO) at Xellia Pharmaceuticals (Denmark), a specialty pharmaceutical company focused entirely on anti-infective treatments against serious and life-threatening infections. Other assignments include memberships at Board of Directors for Active Biotech (Sweden) and Pharmaero (Denmark), as well as being Member of the Scientific Selection Board of Novo Holding’s REPAIR Impact Fund. He has participated in and led development of several novel and patented NCE and specialty pharmaceutical products with special emphasis on the anti-infective therapies. Moreover, he led the development of more than 100 different drug substances (APIs) and development of more than 200 different drug products (FDFs). He has authored more than 20 different patent families with granted patents and patent applications in various patent offices (USPTO, EPO, etc.).